OncoMed Pharmaceuticals and Bayer HealthCare have expanded their collaboration under which Bayer will manufacture clinical supplies of a second Wnt inhibitor. Bayer will manufacture the bulk drug substance at its Berkeley, CA clinical manufacturing center to support Phase I testing, which expected to begin in 2012. “We are pleased to announce this expansion of our partnership with Bayer,” said Paul Hastings, president and chief executive officer of OncoMed Pharmaceuticals. “We continue to mak...